Information  X 
Enter a valid email address

Ferguson PLC (FERG)

  Print      Mail a friend       Annual reports

Thursday 11 July, 2019

Ferguson PLC

Transaction in Own Shares

RNS Number : 2975F
Ferguson PLC
11 July 2019
 

Transaction in own shares

Ferguson plc (the "Company") announces that on 11 July 2019 it purchased for Treasury the following number of its ordinary shares of 10 pence each pursuant to its $500 million share repurchase programme, details of which were announced on 10 June 2019.

Description of shares: Ferguson plc - ordinary shares of 10 pence

Number of shares repurchased: 70,000

Date of transaction: 11 July 2019

Average price paid per share: £57.426687

Lowest price paid per share: £57.200000

Highest price paid per share: £57.640000

Broker: J.P. Morgan Securities plc

The Company intends to hold these Shares in Treasury.

Including shares which have been purchased but not yet settled, the Company holds 1,393,928 Shares in Treasury.

Following the purchase of these shares, the remaining number of ordinary shares in issue will be 230,777,254.

The figure of 230,777,254 may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Disclosure and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), detailed information about the individual purchases is attached to this announcement.

 

http://www.rns-pdf.londonstockexchange.com/rns/2975F_1-2019-7-11.pdf

 

For further information, please contact:

 

Ferguson plc

Mike Powell, Chief Financial Officer

+44 (0)118 927 3800

 

Mark Fearon, Director of Communications and Investor Relations

+44 (0)118 927 3800

+44(0) 7711 875070

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
POSGMGMNVMRGLZM

a d v e r t i s e m e n t